annick schwebig, m.d., · by 2015, it is anticipated that nanomedicine applications will...

1

Key Key ResultsResults of 2008 of 2008 Leem Nanomedecine Study Leem Nanomedecine Study

NanobioNanobio Dialogue Session Dialogue Session

Annick Annick SchwebigSchwebig, M.D.,, M.D.,GeneralGeneral Manager, Manager, Actelion PharmaceuticalsActelion Pharmaceuticals FranceFrance

ViceVice--PresidentPresident of of Leem Biotech CommitteeLeem Biotech Committee

EuroBioEuroBio, Paris, , Paris, OctoberOctober 88thth 20082008

22008 Nanomedecine Study – Eurobio 0ctober 8th 2008

WhyWhy thisthis studystudy ??

Within the Leem (French Pharmaceutical Companies Association), the Leem Biotechnology Commission represents Life Sciences companies that have a strong focus on the red biotech sector.

It positions itself as a think tank that provides the Leem, key decision makers and the general public with analyses, reports and recommendations aiming at foreseeing trends and innovation brought by biotechnologies as well as understanding France attractiveness and competitive position.

Since 2004, the following areas are the main that have been investigated by the Commission: bioproduction, employment, careers and formation in healthcare, cell therapy & tissue engineering

In 2007, the Biotechnology Commission was also particularly involved in the White Book «Health Innovation in 2015» leaded by the Leem Research.

In this context, in 2008, the Leem Biotechnology Commission with the help of consulting firm Bionest Partners, decided to launch a large survey to assess the competitiveness of France in the field of nanomedicine.


NanoproductsNanoproducts size size couldcould bebe beyondbeyond the nanometerthe nanometer scalescale ((betweenbetween 1 1 andand 100 nm)100 nm)

Nanotechnologies lead to the creation of structures, devices and systems where thesize of the active component is comprised between 1 and 100 nanometers (nm)

Nanotechnologies could also encompass elements of a size that exceeds the nanometer scale (e.g. micrometer) but only if the miniaturization confers them new physical properties (e.g. microfluidics, liposomes)

Source: Bionest Partners analysis

Dendrimers Liposomes

Nanoparticules(e.g. nanotubes, fullerenes, quantum dots)

100 nmProtein

101 nmRibosome

102 nmNuclear Pore

103 nmMitochondrion

104 nmCell

>105 nmTissue

10-1 nmH2O

moleculeADN

Virus-Like Particles


TheThe boom boom andand future future developmentdevelopment of of nanomedicinenanomedicine willwill mainlymainly relyrely on on synergies synergies betweenbetween four four scientificscientific areasareas

BiologyBiologyCellularMolecularFunctional

ClinicsClinicsPhysiopathologyTherapeuticsClinical Trials

ChemistryChemistryComplexSupramolecular

PhysicsPhysicsElectrotechnicalElectronicsEngineeringQuantum effects




In In healthcarehealthcare, nanotechnologies applications , nanotechnologies applications couldcould range range fromfromdiagnostic to monitoring of diagnostic to monitoring of treatmentstreatments

Nanotechnologies Nanotechnologies and Healthand Health

Bioassays

Imaging

Monitoring

Diagnostic

In Vitro Diagnostic, Imaging and Biotech industries

Monitoring of therapeuticresponse

Monitoring

Pharma and Med Tech industries

Personalized Medicine

Implants

Drugs

Drug Delivery

Treatment

Pharma, Biotech and Med Tech industries


Benefits of nanometer scale in healthcare

More More specificallyspecifically, nanotechnologies , nanotechnologies allowallow a a betterbetter specificityspecificity and sensibility and sensibility of diagnostics of diagnostics and therapeuticsand therapeutics toolstools

Source: CLINAM, interviews, Bionest Partners analysis

Nanotechnologies allow to get elements that are:

Miniaturized,

Biologically active,

More specific of tissue, cell or subcellular dysfunctional compartment

Nanotechnologies find applications in various medical areas:

Target discovery

Gene or drug delivery

In vitro diagnostic testing (e.g. nanoarray) and in vivo (e.g. contrast agents)

Monitoring tools

Medical applications of nanotechnologies


Benefits

Applications Applications -- New in vitro diagnostic New in vitro diagnostic toolstools

Increase test performance : sensibility, detection threshold, speed

Reliability and accuracy of results

Miniaturization of tools

Biological elements stabilization

Decrease of reagents consumption per analysis (cost reduction)

Sensors

Nanoanalytical tools

Surface microscopy

Imaging mass spectrometry

Advanced ultrasonic technologies

Chemo-sensors

Bio-sensors

Examples


Applications Applications -- New in vivo diagnostic New in vivo diagnostic toolstools

Early detection of diseases

More powerful imaging technologies

Increase of targeting and specificity

Miniaturization of tools

Decrease of detection threshold

Benefits

Imaging markersFluorescent and luminescent particles

Radioactive tracers

Endoscopic probes

Imaging endoscopic shells

Catheters coupled with nanosensors

Examples

Dispositifs


Applications Applications –– New New therapeutictherapeutic toolstools

Increase of drug efficacy

Decrease of adverse effects and limitation of toxicity

Treatment cost reduction (decrease of quantity of active ingredients needed)

More targeted therapies

Development of new therapeutic approaches and mechanism of action

Benefits

Devices

Active nanoelements

Subject to activation

Naturallyactive

Cardiac surgery assistance

Injectable or implantable nanoparticles that could beactivated by ultrasounds or magnetic fields

Embospheres

Drug delivery systems

Liposomes

Nanocristals

Virus-like particles

Examples


In In drugdrug deliverydelivery, , nanoparticlesnanoparticles couldcould open new open new developmentdevelopmentpossibilities possibilities for for toxictoxic molecules molecules

Example : TAK 779 anti-HIV molecule

Satisfactory therapeuticeffects

BUT

Strong adverse effects

Development

stopped

Source: Bowman et al. J Am Chem Soc. 2008, Bionest Partners analysis

Traditional Approach

Nano Approach

TAK 779Active moleculeFREE STATE

Interaction

Cells

Interaction

CellsTAK 779

Active moleculeCOUPLED

Increase of expectedtherapeutic effects

AND

Decrease of adverse effects

Promising results of

TAK 779 coupled

with a nanoparticle

Gold Nanoparticle


Most of Most of nanomedicinenanomedicine patents are patents are concerningconcerning drugdrug deliverydeliveryapplications, applications, the Unitedthe United States States beingbeing particularlyparticularly active in patent active in patent filingfiling

Source: European Patent Office, Bionest Partners analysis

Worldwide nanomedicine patents over the 1993–2003 period

By area By country

Drug delivery59%

In vitro diagnostic14%

Biomaterials8%

Imaging13%

Therapeutic molecules3%

Active implants3%

USA54%

Japan5%

Germany12%

UK3%

France3%

Others23%


By 2015, By 2015, itit isis anticipatedanticipated thatthat nanomedicinenanomedicine applications applications willwill dramaticallydramatically increaseincrease theirtheir shareshare in in the wholethe whole nanotechnologynanotechnology marketmarket

Nanotechnology market

2007 2015

In 2015, the nanomedicine market could represent a $170 billions opportunity

Source: Cientifica, Bionest Partners analysis

Semi-conductors

35%

Defense 3%

Chemical Products

53%

Electronics7%

Nanomedicine2%

$135 billion

Semi-conductors

31%

Chemical Products

9%

Electronics28%

Defense6%

Automotive4%

Others5%

Nanomedicine17%

$1000 billion


Medical Medical nanoproductsnanoproducts are already commercialized, the majority of are already commercialized, the majority of which being drug delivery toolswhich being drug delivery tools


Over thirty products are already commercialized

The majority of products are formulations of existing or newly developed drugs

Nanoproducts on the market

Drug delivery58%

Biomaterials25%

In vivo Imaging8%

In vitro Diagnostic6%

Implants3%

n=36



Liposomes Liposomes and nanocristalsand nanocristals representrepresent the majoritythe majority of of nanodeliverynanodeliveryproductsproducts on on the market the market

Nanodelivery products on the market

Liposome42%

Nanocristal24%

Virosome19%

Micelle5%

Polymer5% Resin

5%

n=21 Ex :daunorubicin in Kaposi Sarcomatreatment, amphotericin B (antifungal)

Ex :HPV vaccines, Hepatitis A vaccines

Ex :Fenofibrate (lowering cholesterol agent), sirolimus (immunomodulator – transplantation)


The US, Japan, Germany and South Korea are the most advanced The US, Japan, Germany and South Korea are the most advanced countries in the countries in the nanomedicinenanomedicine areaarea

Source: Lux research, Bionest Partners

Global competitiveness in nanotechnologies

Cluster #1 : « Dominant countries » where activity, R&D intensity and Government support are very high

Cluster #2 : « Followers »

where effort dedicated to nanotech activities is reasonable

Cluster #3 : « Niche countries »

where limited nanotech activities exist but with an intense commitment of Governments

Cluster #4 : « Laggards » where development intensity is reasonable but level of activities is low

–

+

–

+

Level of

act

ivit

y in

nan

ote

chn

olo

gie

s

Country commitment to support nanotechnology


TwoTwo referencereference centerscenters withwith international international reachreach are are involved involved in in the nanomedicinethe nanomedicine fieldfield in Francein France

Source: réseau Nanomat, interviews, Bionest Partners analysis

International center

National center

Châtenay-Malabry

Besançon

Grenoble

Besides international centers of excellence, centers and research teams with national reach are also involved in the field of nanomedicine

Research team


Public Public fundingfunding of nanotechnologies in Franceof nanotechnologies in France

+ OSEO ANVAR (0,1%)

0

10

20

30

40

50

60

70

80

90

2001 2002 2003 2004 2005

OSEO-ANVAR INSERM MINEFI CEA MESR CNRS

Source: Ministère de l’Enseignement Supérieur et de la Recherche, Bionest Partners analysis

MESR26,5%

MINEFI16,2%

CNRS31,6%

CEA24,5%

277,4 M€

INSERM2,7%

143,5 165,1 210,1 255 277,4

N.B: Total of public funding per year is stated on top of bar charts

N.B: M€ = million euros

Evolution over the 2001–2005 period (M€) Split of public R&D funding (2005)

Public financing


Source: NanoVip, Nanoforum, Nanowerk, Bionest Partners analysis

WithWith 12 active 12 active companiescompanies, France , France presentspresents thethe second concentration second concentration of of nanomedicinenanomedicine companiescompanies in Europein Europe

Medsqual

Research Tools

Diagnostics

Therapeutics (drug delivery)

Therapeutics (active nanoparticles)

1

http://www.bioam.fr/wo/site/public/v_fr/statique/portefeuille/ademtech.php


ExampleExample of of the InNaBioSantthe InNaBioSantéé FoundationFoundation in Toulousein Toulouse

Research Foundation launched in 2005

Goals: definition, promotion and financing of partnerships allowing the development of R&D activities in the Life Sciences field, and in oncology in particular

Actively back the development of Nanotechnologies, Infotechnologies, Biotechnology and differentradiotherapy techniques

Funding of €21.5 million brought by industrials, National Research Agency and Ministry of Research

InNaBioSanté Foundation

Source: InNaBioSanté, Bionest Partners analysis

Nano-Oncology: Development of nanoparticles with magnetic core with application in medical oncology

Modic (MOlecular Diagnostic and Imaging Cancer) : Improvement of early detection and diagnostic of cancer

Oncomate (Olfactive Nano-detection of Cancers Obtained from MAchine-learning Technology)

Examples of projects funded by the Foundation


TheThe FP7 FP7 dedicateddedicated a 730Ma 730M€€ budget for budget for researchresearch and developmentand developmentprojectsprojects in in nanomedicinenanomedicine

Source: Commission Européenne, Bionest Partners analysis

Nanomedicine, Nanobiotechnologies

Other NanotechnologiesB

illion

€Total FP7 :

€50.5 billion

0,01 0,22

0,73

0,11 0,21

1,1

2,74

0

0,5

1

1,5

2

2,5

3

3,5

FP4 FP5 FP6 FP7

0,005

Total FP6 :€17.5 billion

Total FP5 :€14.9 billion

Total FP4 :€12.5 billion 1.4% of total FP7

budget

Framework Program budgets dedicated to nanotechnologies

Besides pure R&D projets, FP 5 et 6 have allowed to finance 14 projects dedicated to assess the environmental impact of nanoparticles

21www.bionest.com

annick schwebig, m.d., · by 2015, it is anticipated that nanomedicine applications will...

Documents